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Abstract
Introduction: Although, on average, cognition declines with age, cognition in older adults is a dynamic process.
Hypertension is associated with greater decline in cognition with age, but whether treatment of hypertension affects this is
uncertain. Here, we modelled dynamics of cognition in relation to the treatment of hypertension, to see if treatment effects
might better be discerned by a model that included baseline measures of cognition and consequent mortality
Methodology/Principal Findings: This is a secondary analysis of the Hypertension in the Very Elderly Trial (HYVET), a double
blind, placebo controlled trial of indapamide, with or without perindopril, in people aged 80+ years at enrollment. Cognitive
states were defined in relation to errors on the Mini-Mental State Examination, with more errors signifying worse cognition.
Change in cognitive state was evaluated using a dynamic model of cognitive transition. In the model, the probabilities of
transitions between cognitive states is represented by a Poisson distribution, with the Poisson mean dependent on the
baseline cognitive state. The dynamic model of cognitive transition was good (R
2=0.74) both for those on placebo and
(0.86) for those on active treatment. The probability of maintaining cognitive function, based on baseline function, was
slightly higher in the actively treated group (e.g., for those with the fewest baseline errors, the chance of staying in that
state was 63% for those on treatment, compared with 60% for those on placebo). Outcomes at two and four years could be
predicted based on the initial state and treatment.
Conclusions/Significance: A dynamic model of cognition that allows all outcomes (cognitive worsening, stability
improvement or death) to be categorized simultaneously detected small but consistent differences between treatment and
control groups (in favour of treatment) amongst very elderly people treated for hypertension. The model showed good fit,
and suggests that most change in cognition in very elderly people is small, and depends on their baseline state and on
treatment. Additional work is needed to understand whether this modelling approach is well suited to the valuation of small
effects, especially in the face of mortality differences between treatment groups.
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Introduction
The ageing process is often associated with worsening health,
however,the population isageing and a means to identify those most
at risk of cognitive decline or dementia, especially in the very elderly
(aged 80 and over) category should be useful [1]. One technique
which has been used for physical health is an index of frailty. The
greater the number of deficits, (which can include symptoms, signs,
diseases and disabilities) the greater the risk of developing further
deficits and the possibility of incident deterioration in health or of
death [2–4,5]. Using a measure or index of frailty to describe
transitions in health states, can include variation in health over time,
including improvement [6]. Based on data from the Canadian Study
of Health and Aging (CSHA) and that from the Gothenburg H70
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11775study a mathematical model based on a Poisson distribution has
been developed to account for the effect of number of deficits over
time and their impact on subsequent mortality [6]. Following this, it
has been suggested that a similar model could be applied to cognitive
function and cognitive decline, such that the greater number of
errors made on a cognitive test the more likely further decline at
subsequent follow up. Using data from the CHSA baseline, five and
10yearvisitsamathematicalmodelofchangeincognitivestates,(the
dynamic model of cognitive transition) was produced [7]. These
cognitive states were based on the cognitive function scores from the
Modified Mini-Mental State Examination (3MS) [8,9]. The fit of the
model was good (R
2=0.96) and as this dynamic model of cognitive
transitions accounted for both improvement and decline in cognitive
function, it may be clinically relevant [7,8]. Full details of the model
used can be found in the methods section.
The CSHA sample was aged $65 years and less than 50
percent were hypertensive [10]. Whether this model would fit an
older (.80 years) population, one that was hypertensive and
whether the influence of anti-hypertensive treatment upon the
probabilities of the model could be established remains to be seen.
This is of interest as the fastest growing segment of society is aged
80 and over, both in developed and developing countries [11].
Due to the physiological effects of ageing, a large proportion of
such older adults suffer from hypertension and there is evidence to
suggest a link between high blood pressure and an increased risk of
cognitive decline and dementia [12]. Further issues that combine
to emphasize the importance of this health problem are the
psychological, physical and financial burdens associated with
caring for those with cognitive decline or dementia [11] and the
recent results from the HYVET trial [13].
The Hypertension in the Very Elderly Trial [HYVET] was
designed to examine the risks and benefits associated with the use of
anti-hypertensive therapy in those aged 80 or more and has recently
reported in favour of anti-hypertensive treatment reducing
mortality, cardiovascular events, stroke and heart failure [13].
TheHYVETtrial alsoassessed cognitivefunctionanddidnot find a
statistically significant result using either interval censored or Cox
proportional hazard survival analyses although the combination of
the HYVET results with other similar trials in a meta-analysis did
produce a summary ratio just significantly in favour of treatment
[14]. If the dynamic model of cognitive transition fits with the
HYVET data it could provide an opportunity to predict outcomes
in very elderly hypertensive people. This high risk group would
potentially allow modelling of the impact of antihypertensive
treatment in a more sophisticated and potentially clinically
applicable fashion. The HYVET data is taken from an older age
group, a hypertensive group, predominantly female and with
shorter follow up than the CSHA data set. The objective of this
investigation was therefore to examine the applicability of this
dynamic model of cognitive transitions and the impact of HYVET
trial antihypertensive treatment upon cognitive functioning using
methodology that may allow the evaluation of more subtle change
than a traditional survival analysis. The model may also provide
some means of predicting future cognitive health state based on
baseline state and mortality risk. Two aims were pursued; 1: to
evaluate the dynamic model of cognitive transitions with the
HYVET data. 2: To use this modelling methodology to evaluate the
impactofanti-hypertensivetreatment inthe HYVETpopulationon
cognitive functioning and to attempt to predict these effects.
Methods
The Hypertension in the Very Elderly Trial was a double
blind placebo controlled trial investigating the risks and benefits
associated with the use of anti-hypertensive treatment in the very
elderly. Full details of the protocol and results have already been
published elsewhere [15,16]. Briefly, in order to enter the trial
participants had to be aged 80 or over at the time of
randomisation, have a systolic blood pressure of .=160mmHg
and ,200mmHg sitting and .=140mmHg standing with a
sitting diastolic pressure of ,110mmHg. Participants could not
enter HYVET if they required ongoing nursing care, were
s u f f e r i n gf r o mac o n d i t i o nt h a tw o u l ds e v e r e l yl i m i tt h e i rl i f eo r
had received a clinical diagnosis of dementia. Treatment was
with indapamide Slow Release[SR] 1.5mg, (or matching
placebo) daily with the option of additional perindopril 2–4mg
(or matching placebos) to reach a goal blood pressure of ,150/
80mmHg. Participants had their cognitive function assessed at
baseline and annually thereafter with the Mini-Mental State
Exam [MMSE]. Mortality data was also collected as part of the
trial. The first description of the dynamic model of cognitive
transition used the 3MS. The 3MS was split into categories to
represent ranges of 3MS scores with clinically detectable
differences in cognitive performance, i.e. to represent distin-
guishable cognitive health states [7,8]. The model takes account
of four factors, (1) the background expectation of accumulating
additional errors, (2) the background and (3) increment in the
probability of dying (based on the level of cognitive deficit) and
(4) the increment in the expectation of incurring more or fewer
errors, again based on the level of baseline cognitive deficits. In
HYVET cognitive function data was collected using the MMSE
which was similarly split into cognitive health states using ranges
of the MMSE score (see below). The dynamic model of cognitive
transitions was then applied to the HYVET data, using
information from mortality and cognitive function assessments
at baseline and after two and four year follow up, and change
between these visits. Details of the model are below. Four year
follow up was similar to that used in the CSHA and H-70
analyses and two year follow up was used because the
participants were older, may show faster decline and because
the mean follow up for the cognitive function aspect of HYVET
trial was 2 years.
Categorising cognitive health in HYVET
Cognitive health can be describedi nr e l a t i o nt oa ni n c r e a s i n g
number of cognitive deficits, represented by errors on a
cognitive test. The MMSE in HYVET was categorised into
those with 0–2 errors (cognitive health state 0), i.e. a score of
28–30, 3–5 errors (cognitive health state 1), a score of 25–27, 6–
8 errors (cognitive health state 2), a score of 22–24, and so on.
This is in line with the concept of deficit accumulation in
relation to cognitive categories, as used with the 3MS data from
the CSHA. Here, the categories are used in the model to
measure the movement of participants between these cognitive
health states. These categories of MMSE score were chosen to
ensure clinical relevance and are similar to the frequently used
cut-off values for MMSE score when used as a screening
instrument for dementia [17]. The probability of changing from
o n ec o g n i t i v es t a t et oa n o t h e r( i ne ither direction, i.e. improved
MMSE score resulting in a higher cognitive health state or a fall
in MMSE score resulting in a lower cognitive health category)
was then calculated for the HYVET data. Note that the model
allows all clinically relevant outcomes (improvement, decline,
stability, death) to be modelled simultaneously. The model was
t h e na p p l i e dt ot h eH Y V E Td a t a b a s ea n df u r t h e ru s e dt o
evaluate the effects of the active versus the placebo trial
medication.
Modelling Cognitive Decline
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We assume that the data collated can be described by a Markov
process p consisting of the probabilities pkn that a patient moves to
class k from class n over a 24-month period, where the class ranges
from 0 to 9. Each class represents a different mental state of the
patient and is calculated from an MMSE score via an association
30, 29, 28 fg ?0, 27,26, 25 fg ?1 down to 3,2,1 fg ?9,
assuming a score of 0 cannot be achieved on an MMSE.
Furthermore, for each mental state, n, there is an associated
probability of death over a 24-month period for that state pdn,
where the subscript d denotes death and not a numerical value.
As a result, the process p can be represented by an 11611
stochastic matrix whose entries are the numbers pkn and pdn:
p~
P 0
d 1
  
where the (k,n)-th entry in the 10610 matrix P is pkn and d=(pd0,
pd1,…, pd9). In this formulation death represents a state of each
patient that once entered, cannot be escaped; such a state is called
an absorbing state.
A schematic representation of three states that define the
process p, is below illustrating some of the transitions between
states 0, 1 and d, and their associated probabilities, state d is the
absorbing state. The full model has eleven such states, see figure 1.
Following (Mitniski and Rockwood, 2008) [7] we assume a
modified Poisson distribution for pkn of the form
pkn~An
r(n)
k
k!
,
subject to P(death occurs | patients mental state at time zero is
n)=pdn.
Conservation of probability then dictates
pdnz
X 9
k~0
pkn~1 so that pdnzAn
X 9
k~0
r(n)
k
k!
~1
and the approximation
pdnzAn
X ?
k~0
r(n)
k
k!
&1 so that pdnzAn exp(r(n))&1
leads us to define An~(1{pdn)exp({r(n)). Finally therefore,
pkn~(1{pdn)exp({r(n))
r(n)
k
k!
provides the values needed to define the process p.
A two-parameter exponential model [4] was used for the
probability of death pdn, namely pdn=aexp(bn) for parameters a
and b that are first determined numerically from a least-squares fit
to the death data of the 24-month survey for both active and
placebo groups. In Mitniski, Bao and Rockwood, 2006 [2] the 2-
parameter model
r(n)~azbn
was proposed and so we also adopt this form for r(n) which renders
pkn (and therefore p also) a function of the parameters a and b.
We then determine the parameter pair (a, b) so that the least
squares residual
e(a,b)~
X 4
k,n~0Dpkn(a,b){pdata
kn D
is minimised, noting that the summation terminates at state 4 and
not 9 because MMSE data is only available for those states. The
term pkn
data denotes the frequency of patients surveyed and found
to be in mental state k at a time 24 months after the initial MMSE
test at which the patient was in state n.
Due to the approximations made, this minimisation procedure
does not necessarily result in a stochastic matrix p and there are
different remedies to this; we chose simply to scale each column of
p to sum to unity in order to enforce stochasticity.
The software packages used were Matlab and SAS v9.1.
The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Results
The HYVET trial randomised 3845 participants of whom 3336
provided longitudinal MMSE data. There were 739 participants
available for analysis in the active group at two years and 699 in
the placebo group with the majority in the cognitive health states
representing better cognitive functioning.
Model
The dynamic model of cognitive transitions was applied to the
HYVET data and used to create a plot showing the change in
health state, by baseline health state and per treatment group.
The results can be seen in figures 2 (placebo group) and 3 (active
group). The graphs show both the surveyed (i.e. collected data)
Figure 1. A diagram showing the basis of the model.
doi:10.1371/journal.pone.0011775.g001
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figure there are five graphs, the first graph represents those
participants who were in cognitive health state 0 (MMSE 28–30)
at the trial baseline. The x axis shows the cognitive health state
that they had attained after two year follow up and the
probability of falling into the later cognitive health state is shown
on the y axis. Thus it can be seen that the majority of those
participants who started the trial in cognitive health state 0, were
cognitively intact and remained so after two years. The data from
the trial participants is indicated by circles on the graph. The
second graph presents the same information for those who
entered the trial in cognitive health state 1 and so on for both the
placebo and actively treated groups. Participants could not enter
the HYVET trial if they had a clinical diagnosis of dementia and
this meant that the full range of MMSE scores was not present at
trial baseline.
In both treatment groups it can be seen that the higher the
baseline cognitive health state the higher the likelihood of
remaining in that cognitive health state, although it should be
remembered that the maximum score on the MMSE is 30 and
that ceiling effects are likely to apply. The model showed a
relatively good fit to the HYVET data with the R
2 for the two year
follow up data at R
2=0.74 for the placebo group and R
2=0.86
for the active group. In order to test the model further it was
extrapolated to predict four year follow up data which was then
compared back to the collected, i.e. real data from the trial.
Although the numbers for analysis in the trial at four year follow
up (342) were less than at two years, this still resulted in R
2 values
of R
2=0.78 for the placebo group and R
2=0.72 for the active
group.
Predicting cognitive health state after two year follow up
The model was then used to predict the probability of moving
from one health state to the next in numerical form thus allowing
the creation of a ‘risk table’ such that future health/cognitive state
can be predicted based on current state and taking account of
antihypertensive treatment. Tables 1 and 2 provide these
probabilities. Each treatment group is represented by one table
where the columns represent the cognitive health state at baseline
and the rows the cognitive health state attained at two years. For
example, the probability of remaining in cognitive health state 0 at
two years and in the placebo group (table 1) is 0.60. The tables
show that, according to the model as based on the HYVET data,
the probability of maintaining cognitive function based on baseline
function may be slightly higher in the actively treated group. The
actively treated group maintained a very slightly higher probability
of remaining in their baseline cognitive health states. Although the
figures in the table are derived from the model the patterns were
very similar when examining the raw data, (for example the
probability of remaining in cognitive health state 0 was 0.559 in
the actively treated group versus 0.497 in the placebo group).
Numbers were small however and so further analysis using
bootstrapping techniques and the adjusted bootstrap percentile
method was carried out. This resulted in means and 95%
confidence intervals for change in MMSE score of (a fall of)
1.91 (1.63–2.23) for the active group, compared to 2.03 (1.72–
2.38) for the placebo group.
Figure 4 presents the same information in the form of ‘bars’ of
probability with the actively treated group demonstrating a greater
probability of participants remaining in the upper, cognitively
stable section.
Figure 2. A graph showing change in health state (placebo group) at two years, by baseline health state.
doi:10.1371/journal.pone.0011775.g002
Modelling Cognitive Decline
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corresponding graphs are available in Appendix S1 and Figures
S1 and S2.
Mortality
When mortality was examined, the risk of mortality in the placebo
group was greater in those with greater cognitive deficits. This pattern
was not clearly seen in the active group although it must be remem-
bered that active treatment reduced mortality in the trial overall.
Discussion
The HYVET data on cognitive health state change and based
on cognitive health state fits with the recently proposed dynamic
model of cognitive transitions. The innovative aspect of our
analysis is the incorporation of mortality in the assessment and we
consider that this will be welcomed by researchers and therapists
alike. Furthermore, the application of the model to the HYVET
data suggests that there is a possibility that anti-hypertensive
Figure 3. A graph showing change in cognitive health state (active group) at two years, by baseline health state.
doi:10.1371/journal.pone.0011775.g003
Table 1. Change in MMSE over two years - placebo group.
Probability of moving from (baseline) MMSE score…
Cognitive health state MMSE 28–30 0 MMSE 25–27 1 MMSE 22–24 2 MMSE 19–21 3 MMSE 16–18 4
to MMSE score at two years of… MMSE 28–30 0 0.60 0.29 0.09 0.02 0.00
MMSE 25–27 1 0.23 0.30 0.23 0.12 0.05
MMSE 22–24 2 0.09 0.19 0.23 0.20 0.12
MMSE 19–21 3 0.03 0.10 0.17 0.20 0.17
MMSE 16–18 4 0.01 0.05 0.11 0.16 0.18
MMSE 13–15 5 0.01 0.02 0.06 0.11 0.15
MMSE,13 .5 0.00 0.02 0.06 0.14 0.26
death 0.02 0.03 0.04 0.05 0.06
Mortality 0.02 0.03 0.04 0.05 0.06
Cognitive decline 0.38 0.38 0.41 0.42 0.41
Cognitive Improvement/Stability 0.60 0.59 0.55 0.53 0.53
doi:10.1371/journal.pone.0011775.t001
Modelling Cognitive Decline
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Probability of moving from (baseline) MMSE score…
Cognitive health state MMSE 28–30 0 MMSE 25–27 1 MMSE 22–24 2 MMSE 19–21 3 MMSE 16–18 4
to MMSE score at two years of… MMSE 28–30 0 0.63 0.30 0.08 0.01 0.00
MMSE 25–27 1 0.22 0.32 0.25 0.13 0.05
MMSE 22–24 2 0.08 0.19 0.25 0.22 0.15
MMSE 19–21 3 0.03 0.09 0.17 0.21 0.20
MMSE 16–18 4 0.01 0.04 0.10 0.16 0.19
MMSE 13–15 5 0.00 0.02 0.05 0.10 0.15
MMSE,13 .5 0.00 0.01 0.05 0.12 0.23
death 0.02 0.02 0.04 0.03 0.02
Mortality 0.02 0.02 0.04 0.03 0.02
Cognitive decline 0.35 0.36 0.37 0.38 0.38
Cognitive Improvement/Stability 0.63 0.62 0.58 0.58 0.59
doi:10.1371/journal.pone.0011775.t002
Figure 4. Probability of change over two years by baseline health state.
doi:10.1371/journal.pone.0011775.g004
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be confirmed by additional studies. Even so, these analyses suggest
that people treated with anti-hypertensives may maintain their
cognitive health state for longer, something that was not shown
statistically here but which clearly merits further investigation. If,
as is implied by our findings, anti-hypertensive treatment slows or
prevents further decline, it may be useful in terms of allowing those
with early cognitive decline to function independently for longer or
act as an incentive for patients to adhere with treatment regimens.
The tables of probabilities allow some element of prediction and
may be useful for health care professionals planning future patient
reviews, resources, and initiating currently available or even future
treatments. Again, this utility needs to be demonstrated in further
studies. It is argued that the table that should receive the greatest
focus is that from the actively treated group since the HYVET trial
clearly showed benefit from treatment in elderly hypertensives for
mortality, stroke and heart failure and such treatment may be
expected to be given in the future. Further exploration of other
factors that may impact upon cognitive function would be a useful
addition to such tables as would information relating to change in
profile of risk factors with increasing age, such as cholesterol level,
risk behaviours such as smoking etc.
There are several benefits associated with the use of this model.
First, it allows representation of change in all directions
(improvement, decline and mortality) simultaneously, as compet-
ing events. Second, it allows for graduated changes in cognition
(both declines and improvements) to be assessed. Third, it is
parsimonious; it is based on Poisson distribution. Fourth, it allows
precise parameters estimation. The technique can be used by using
Poisson regression models that are readily available in many
statistical software packages as a part of Generalized Linear Model
programming. Fifth, it is easily interpretable. The intercepts of the
Poisson mean and of the probability of death characterize
transition of the people who had the best cognitive performance
at baseline and therefore can be used in studying the factors
influencing such performance to better understanding the initial
stages of impairment. Despite this, however, our analyses must be
interpreted with caution. As the method is new, it requires
additional use to understand its full range of advantages and
limitations.
In addition, we are limited by having the MMSE as the global
cognitive measure. Whilst a good pragmatic choice, it is not an
ideal assessment of cognitive functioning and suffers from ceiling
effects, even in very elderly people [9,17]. It may also be necessary
to follow participants for longer than two years in order to fully
evaluate the impact of any treatment. Because HYVET was
stopped early this was not possible in this cohort. It is argued that
this area merits a study with the focus upon change in cognitive
function as an outcome and the impact of anti-hypertensive
treatment and other risk factors and interventions examined.
Further research and collaboration is also required in order to
expand the ‘risk tables’ presented here to incorporate other key
factors in cognitive ageing and allow potential targeted interven-
tions as and when further treatments to ameliorate or prevent
cognitive decline become available.
Conclusions
Using a model which takes into account risk of mortality and of
increase as well as decrease in cognitive performance data from
the Hypertension in the Very Elderly [HYVET] Trial suggests
that antihypertensive treatment may reduce risk of cognitive
decline. Caution must be applied as the differences between the
active and placebo groups were not large or significantly different
and mortality was reduced with active treatment, however, it is
argued that this highlights the need for further and more
sophisticated studies. Such future work should include exploration
of risk factors that could allow the development of risk tables for
cognitive decline.
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